News about Global Pharma

Merck to Acquire CN201 from Curon Biopharmaceutical

CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for treating patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively.

Global Pharma | 14/08/2024 | By Aishwarya |  449

Persist AI and Nivagen to Develop AI-Driven Manufacturing Process for LAI Drugs

The collaboration aims to simplify and accelerate the development and approval of LAI drugs, which can provide sustained and controlled release of drugs over weeks or months, improving patient adherence and outcomes.

Global Pharma | 13/08/2024 | By Aishwarya |  659

Champalimaud Foundation to Leverage Lonza Platform to Advance Cell Therapy

Champalimaud Foundation, a biomedical clinical research organization carrying out research and cutting-edge clinical development and discoveries that benefit people, and Lonza have announced the installation of Lonza’s MODA-ES Platform at the Champalimaud Clinical Centre in Lisbon, Portugal.

Global Pharma | 13/08/2024 | By Aishwarya |  930

Biosyngen Gets FDA Approval for BRG01 for Phase II Clinical Trial

Biosyngen has announced that the US Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial.

Global Pharma | 13/08/2024 | By Aishwarya |  498

Granules India Gets ANDA Approval for Trazodone Tablets

Granules now has 65 ANDA approvals from the US FDA (64 final approvals and 1 tentative approval). The current annual US market for Trazodone tablets is approximately USD 128 Million.

Global Pharma | 12/08/2024 | By Aishwarya |  873

Samsung Biologics Joins Pharmaceutical Supply Chain Initiative as Supplier Partner

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner.

Global Pharma | 08/08/2024 | By Aishwarya |  709

Valeo Pharma Announces Appointment of New CEO

Valeo Pharma Inc. has announced that the company’s Chief Development Officer, Al Moghaddam, has been appointed to succeed retiring CEO Steve Saviuk.

Global Pharma | 07/08/2024 | By Aishwarya |  1313

Gland Pharma Reports 16 Percent YoY Revenue Growth in Q1FY25

Gland Pharma has revealed its financial results for the first quarter of FY25, ending June 30, 2024.

Global Pharma | 07/08/2024 | By Aishwarya |  715

Antengene Gets Malaysian Regulatory Agency Approval for XPOVIO Commercialization

Antengene has announced that Malaysian National Pharmaceutical Regulatory Agency has approved a New Drug Application (NDA) for XPOVIO (selinexor).

Global Pharma | 06/08/2024 | By Aishwarya |  711

Skanray Partners with Tata Elxsi to Power Surgical Imaging Technology

Skanray has selected Tata Elxsi as a strategic partner for advanced surgical imaging core technology and software platform development.

Global Pharma | 05/08/2024 | By Aishwarya |  777